Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Cevimeline Hydrochloride
Generic Name
Cevimeline Hydrochloride
Active Ingredient
CevimelineCategory
Other
Salt Form
Hydrochloride
Variants
13
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30 mg/1 | CAPSULE | ORAL | 33342-216 |
| 30 mg/1 | CAPSULE | ORAL | 71335-2264 |
| 30 mg/1 | CAPSULE | ORAL | 71335-2326 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Cevimeline Hydrochloride, you must consult a qualified healthcare professional.
| 30 mg/1 | CAPSULE | ORAL | 0713-0937 |
| 30 mg/1 | CAPSULE | ORAL | 63629-9863 |
| 30 mg/1 | CAPSULE | ORAL | 0054-0334 |
| 30 mg/1 | CAPSULE | ORAL | 72888-118 |
| 30 mg/1 | CAPSULE | ORAL | 16571-657 |
| 30 mg/1 | CAPSULE | ORAL | 40032-999 |
| 30 mg/1 | CAPSULE | ORAL | 72162-2563 |
| 30 mg/1 | CAPSULE | ORAL | 72789-457 |
| 30 mg/1 | CAPSULE | ORAL | 43386-999 |
+ 1 more variants
Detailed information about Cevimeline Hydrochloride
Cevimeline is a cholinergic agonist primarily used to treat dry mouth (xerostomia) in patients with Sjögren's syndrome. It works by stimulating specific muscarinic receptors to increase glandular secretions.
The standard recommended dosage of Cevimeline for adults with Sjögren's syndrome is 30 mg taken three times daily. This frequency is designed to maintain therapeutic levels of the drug in the bloodstream, as the half-life is relatively short (3-5 hours). Dosing is typically spaced out to coincide with meal times or approximately every 6 to 8 hours to ensure continuous relief from dry mouth symptoms throughout the day.
In some clinical settings, a healthcare provider may start a patient on a lower frequency to assess tolerance, but the 90 mg total daily dose is the established effective level for most patients. It is vital not to exceed this dosage, as higher doses significantly increase the risk of systemic cholinergic toxicity without providing proportional increases in salivary flow.
The safety and effectiveness of Cevimeline in pediatric patients (under the age of 18) have not been established. Clinical trials for Sjögren's syndrome typically focus on adult populations, as the disease is rarely diagnosed in children. Consequently, Cevimeline is not currently approved for pediatric use. If a child suffers from severe xerostomia, specialized pediatric rheumatologists or oral medicine specialists must determine the appropriate course of action, which may involve other therapeutic modalities.
Cevimeline is primarily excreted by the kidneys. While specific dosage adjustment scales based on Creatinine Clearance (CrCl) are not provided in the standard labeling, healthcare providers are advised to exercise extreme caution when prescribing Cevimeline to patients with significant renal insufficiency. Decreased kidney function can lead to the accumulation of the drug and its metabolites, increasing the risk of adverse effects.
Since Cevimeline is metabolized by the liver (specifically via CYP2D6 and CYP3A4), patients with hepatic impairment (liver disease) may have reduced clearance of the drug. Close monitoring for side effects is required in these patients, and a dose reduction may be considered by the treating physician.
Clinical studies did not show overall differences in safety or effectiveness between elderly and younger patients. However, because elderly patients are more likely to have decreased renal, hepatic, or cardiac function, as well as concurrent medications, the standard practice is to start at the lower end of the dosing range and monitor closely for adverse reactions.
Cevimeline should be taken exactly as prescribed by your healthcare provider. The following guidelines are typically recommended:
If you miss a dose of Cevimeline, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects like excessive sweating and abdominal cramping.
An overdose of Cevimeline can lead to a 'cholinergic crisis.' Symptoms of overdose may include severe abdominal cramps, diarrhea, nausea and vomiting, excessive salivation, extreme sweating (diaphoresis), blurred vision, tremors, and potentially dangerous changes in heart rate or blood pressure. In severe cases, it can cause respiratory distress or collapse.
If an overdose is suspected, seek emergency medical attention immediately or contact a poison control center. Treatment usually involves supportive care and, in severe cases, the administration of an anticholinergic agent like atropine to reverse the muscarinic effects.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could result in a return of severe dry mouth symptoms.
Because Cevimeline is a cholinergic agonist, it stimulates various glands and smooth muscles throughout the body, not just the salivary glands. This systemic action leads to several common side effects. According to clinical trial data, the most frequently reported side effects include:
Cevimeline is a potent medication that affects the autonomic nervous system. Patients must be aware that while it treats dry mouth, its effects are systemic (throughout the entire body). It is crucial to disclose your full medical history to your doctor, particularly any history of heart, lung, or kidney problems. Cevimeline is not a cure for Sjögren's syndrome; it is a symptomatic treatment that requires ongoing management.
No FDA black box warnings for Cevimeline. While it lacks the most severe level of FDA warning, it carries significant 'Precautions' and 'Warnings' sections in its official labeling regarding its effects on the heart and lungs.
There are certain medications that should never be used in combination with Cevimeline due to the high risk of adverse outcomes:
There are specific medical conditions where the use of Cevimeline is strictly prohibited because the risks clearly outweigh any potential benefits:
Cevimeline is classified under the older FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. Data from animal studies indicated a slight increase in skeletal variations when very high doses were administered.
Therefore, Cevimeline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally recommended that women who are pregnant or planning to become pregnant discuss alternative ways to manage dry mouth symptoms with their rheumatologist and obstetrician.
It is not known whether Cevimeline is excreted in human milk. Many drugs are secreted in milk, and because of the potential for serious adverse reactions in nursing infants from Cevimeline (such as excessive sweating, diarrhea, or heart rate changes), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
As previously noted, the safety and effectiveness of Cevimeline in children have not been established. Sjögren's syndrome is exceedingly rare in the pediatric population. If xerostomia occurs in a child due to other causes (such as radiation or other autoimmune issues), other treatments with more established pediatric data are usually preferred.
Cevimeline is a quinuclidine derivative of acetylcholine. Its primary molecular mechanism involves acting as a direct-acting cholinergic agonist. It binds specifically to muscarinic receptors. While it can bind to various subtypes, its therapeutic effect in Sjögren's syndrome is mediated through the M3 muscarinic receptors located on the acinar cells of the salivary glands.
Upon binding to the M3 receptor, Cevimeline activates a Gq-protein signaling pathway. This stimulates the enzyme phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the endoplasmic reticulum, causing a release of stored calcium into the cytoplasm. This surge in intracellular calcium triggers the fusion of secretory vesicles with the cell membrane and activates ion channels, leading to the secretion of water, electrolytes, and enzymes into the salivary ducts.
The pharmacodynamic effect of Cevimeline is the stimulation of exocrine glands. The onset of increased salivary flow usually occurs within 30 to 60 minutes of oral administration. The duration of this effect typically lasts for 3 to 5 hours, which is why three-times-daily dosing is required for sustained relief. Beyond the salivary glands, Cevimeline also increases secretions in the digestive tract, the respiratory tract, and the sweat glands, and increases the tone of smooth muscle in the bladder and GI tract. Tolerance to the secretory effects has not been widely reported in long-term clinical use.
Common questions about Cevimeline Hydrochloride
Cevimeline is primarily used to treat the symptoms of dry mouth (xerostomia) in people with Sjögren's syndrome, an autoimmune condition. It works by stimulating specific receptors in the salivary glands to produce more saliva. This helps patients who have difficulty swallowing, speaking, or chewing due to a lack of natural moisture. It is important to note that it does not cure the underlying autoimmune disease but manages the symptoms. Your doctor will determine if you have enough functional gland tissue for the medication to be effective. It is usually taken three times a day to provide consistent relief throughout the day.
The most common side effect reported by patients taking Cevimeline is excessive sweating, also known as diaphoresis, which affects nearly 20% of users. Other frequent side effects include nausea, runny nose (rhinitis), and diarrhea, all of which are related to the drug's stimulation of the parasympathetic nervous system. Some patients also experience dizziness, blurred vision, or an increased urge to urinate. These side effects are often most noticeable when starting the medication and may decrease over time. However, if they become severe or intolerable, you should contact your healthcare provider. They may suggest taking the medication with food to help with nausea.
There is no known direct chemical interaction between alcohol and Cevimeline, but caution is highly recommended. Alcohol is a natural diuretic and can lead to dehydration, which significantly worsens the symptoms of dry mouth that Cevimeline is trying to treat. Additionally, both alcohol and Cevimeline can cause side effects like dizziness and lightheadedness. Combining them can increase the risk of falls or impaired coordination. For the best results in managing Sjögren's syndrome, it is usually best to limit alcohol consumption. Always discuss your lifestyle habits with your doctor when starting a new prescription.
Cevimeline is considered a Pregnancy Category C medication, meaning there is limited data on its safety in human pregnancy. Animal studies have shown some potential for minor skeletal issues in fetuses at very high doses, but these results do not always predict human outcomes. Because the risks are not fully understood, Cevimeline should only be used during pregnancy if the potential benefit to the mother clearly outweighs the risk to the baby. If you are pregnant or planning to conceive, you must discuss this with your healthcare provider. They may recommend alternative treatments or closer monitoring during your pregnancy. Breastfeeding is also generally discouraged while taking this medication as it is unknown if it passes into breast milk.
Most patients begin to notice an increase in saliva production within 30 to 60 minutes after taking a dose of Cevimeline. The peak effect usually occurs around 1.5 to 2 hours after administration. However, the drug's effects are temporary and typically wear off after 3 to 5 hours, which is why it must be taken three times daily. While the physical stimulation of the glands is rapid, it may take a few weeks of consistent use to fully appreciate the improvement in oral comfort and swallowing. If you do not notice any improvement after several weeks of regular use, consult your doctor. They may need to re-evaluate your diagnosis or the functional status of your salivary glands.
Yes, you can stop taking Cevimeline suddenly without experiencing dangerous withdrawal symptoms, as it is not a habit-forming medication. However, because Cevimeline only provides temporary relief of dry mouth symptoms, stopping it will cause your xerostomia to return quickly, often within a day. This can lead to immediate discomfort and an increased risk of oral health problems like cavities or infections. It is always best to talk to your doctor before stopping any prescribed medication. They can help you decide if a different treatment or a different dosage might be more appropriate for your needs. Never stop a medication because of side effects without seeking medical advice first.
If you miss a dose of Cevimeline, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply take the next one at the regular time. Never take two doses at once to 'catch up,' as this significantly increases the risk of side effects like severe sweating, nausea, and abdominal cramps. Maintaining a consistent schedule is the best way to ensure your dry mouth symptoms are managed effectively throughout the day. Using a pillbox or a phone reminder can be helpful for medications that require three-times-daily dosing. If you frequently miss doses, discuss this with your healthcare provider.
Weight gain is not a commonly reported side effect of Cevimeline in clinical trials. The medication primarily affects glandular secretions and smooth muscle activity rather than metabolism or appetite. However, some patients might find that because their dry mouth is improved, they are able to eat more comfortably and may consume more calories as a result. Conversely, some patients might experience weight loss if they suffer from persistent nausea or diarrhea while taking the drug. If you notice significant or unexplained changes in your weight while taking Cevimeline, you should discuss this with your doctor. They can help determine if the change is related to the medication or another underlying health issue.
Cevimeline can interact with several types of medications, so a full review of your current drug list is essential. It should not be taken with other cholinergic drugs or certain heart medications like beta-blockers, as this can cause dangerous changes in heart rate. Additionally, medications with 'anticholinergic' effects (like many antidepressants, antihistamines, and over-the-counter sleep aids) can cancel out the benefits of Cevimeline. Drugs that affect liver enzymes, specifically CYP2D6 and CYP3A4, can also change how your body processes Cevimeline. Always provide your doctor and pharmacist with a complete list of all prescriptions, supplements, and herbal remedies you are using. This allows them to check for potential interactions before you start treatment.
Yes, Cevimeline is available as a generic medication in the form of 30 mg capsules. The brand name version is known as Evoxac. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove 'bioequivalence,' meaning they work the same way in the body. Choosing the generic version can often significantly reduce the out-of-pocket cost for patients. If you have questions about whether the generic is right for you, or if your insurance covers it, speak with your pharmacist or healthcare provider. Most pharmacies stock the generic version due to its wider affordability.
Other drugs with the same active ingredient (Cevimeline)
While rare, some side effects of Cevimeline require urgent medical intervention.
> Warning: Stop taking Cevimeline and call your doctor immediately if you experience any of the following:
There is limited evidence suggesting that Cevimeline causes permanent damage with long-term use; however, the persistent nature of its side effects (like sweating or GI upset) can impact a patient's quality of life. Long-term use requires regular monitoring of dental health, as the medication is intended to prevent the complications of dry mouth, but patients must still maintain rigorous oral hygiene. There is a theoretical risk that chronic overstimulation of the gallbladder or kidneys could contribute to the formation of stones (cholelithiasis or nephrolithiasis) in susceptible individuals.
As of 2024, there are no FDA black box warnings for Cevimeline. However, this does not mean the drug is without risk. The precautions regarding cardiovascular and pulmonary health are considered significant clinical warnings that must be discussed with a physician.
Report any unusual symptoms or changes in your health to your healthcare provider promptly. They may need to adjust your dose or switch you to an alternative therapy if side effects become intolerable.
Patients taking Cevimeline do not typically require frequent blood draws for drug levels, but they should have regular check-ups including:
Use caution when driving at night or performing hazardous tasks in reduced lighting. The pupil-constricting effect of Cevimeline can make it difficult to perceive depth or see obstacles in the dark. If you experience blurred vision or significant changes in your sight, avoid driving until you have consulted your doctor.
While there is no direct chemical interaction between Cevimeline and alcohol, alcohol can cause dehydration and dry mouth, which counteracts the purpose of the medication. Furthermore, both substances can cause dizziness or lightheadedness, and using them together may increase the risk of falls or accidents.
Cevimeline does not typically require a tapering schedule (gradually reducing the dose), as it does not cause a traditional withdrawal syndrome. However, stopping the medication will result in a relatively rapid return of dry mouth symptoms, usually within 24 to 48 hours. Always consult your doctor before stopping the medication to discuss alternative management strategies for your Sjögren's symptoms.
> Important: Discuss all your medical conditions, especially any history of asthma, heart disease, or glaucoma, with your healthcare provider before starting Cevimeline.
Cevimeline is not known to significantly interfere with common laboratory tests (such as basic metabolic panels or complete blood counts). However, because it can affect heart rhythm, it may cause changes on an Electrocardiogram (ECG/EKG).
For each major interaction, the management strategy usually involves either avoiding the combination, adjusting the dose of one of the medications, or increasing the frequency of clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines and sleep aids, as many of these have 'hidden' anticholinergic effects.
In these cases, a healthcare provider must perform a careful risk-benefit analysis before prescribing Cevimeline:
There is no documented cross-sensitivity between Cevimeline and unrelated drug classes. However, patients who have had adverse reactions to other cholinergic agents, such as pilocarpine (Salagen), are more likely to experience similar side effects with Cevimeline, as they share the same mechanism of action.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of eye disease or respiratory issues, before prescribing Cevimeline to ensure it is safe for you.
In clinical trials, approximately 13% of subjects were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, the elderly are more prone to:
Cevimeline is heavily cleared by the kidneys. In patients with significant renal impairment (Stage 3 chronic kidney disease or worse), the drug's half-life may be extended. There is no specific data on dialysis clearance, but patients on dialysis should be monitored with extreme caution for signs of cholinergic overdose.
Because the liver's CYP450 system is responsible for the majority of Cevimeline's metabolism, patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) may experience significantly higher drug exposure. Dose adjustments or increased intervals between doses may be necessary, though no specific guidelines are established in the manufacturer's labeling.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, nursing, or have underlying organ dysfunction before starting this medication.
| Parameter | Value |
|---|---|
| Bioavailability | High (Rapidly absorbed) |
| Protein Binding | < 20% |
| Half-life | 3 - 5 hours |
| Tmax | 1.5 - 2.0 hours |
| Metabolism | Hepatic (CYP2D6, CYP3A4) |
| Excretion | Renal (>90% as metabolites) |
Cevimeline is classified as a cholinergic agonist or parasympathomimetic agent. Within this class, it is further categorized as a muscarinic agonist. It is therapeutically similar to pilocarpine (Salagen), though it has a slightly different receptor affinity profile and a longer half-life.